

elaprase[™] (idursulfase) HUNTER SYNDROME WEBCAST



Dear Medical Professional,

Shire Human Genetic Therapies invites you to participate in a Webcast discussion of the first approved biopharmaceutical treatment for Hunter syndrome and the pivotal Phase II/III clinical study data of ELAPRASE[™] (idursulfase).

Mucopolysaccharidosis type II (MPS II or Hunter syndrome) is an X-linked recessive condition caused by the deficiency or absence of the lysosomal enzyme iduronate-2-sulfatase (I2S). This enzyme is required for the breakdown and re-cycling of mucopolysaccharides (glycosaminoglycans, GAG) throughout the body and in connective tissue elements: skin, bone, cartilage, ligaments, heart valves, airways, meninges, and corneas. Accumulation of GAG can also occur in the brain, causing progressive neurodegenerative disease.

Joseph Muenzer, MD, PhD, Specialist in Pediatric Genetics and Metabolism, Associate Professor, University of North Carolina at Chapel Hill, and lead investigator of the pivotal Phase II/III study, will review the latest clinical data on ELAPRASE, now approved by Health Canada.

The presentation will be followed by a Q&A session during which Dr. Muenzer will reply to your e-mail questions.

David Whiteman, MD, Principal Medical Director, Global Medical Affairs, Shire HGT will introduce Dr. Muenzer and moderate the discussion.

WHEN: October 11, 2007 at 12 p.m., noon, Eastern Time

Register and perform a system test as soon as possible by clicking here:
www.romedia.com/hunter/index.html

By registering early we will be able to send you a reminder notice.

We hope you'll be able to join us.

For information: please contact webcasts@romedia.com or 1 877 990 9044
Presented by the Canadian Division of Shire Human Genetic Therapies, Inc.